{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Classic+Hodgkin+Lymphoma&page=2", "query": { "condition": "Classic Hodgkin Lymphoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Classic+Hodgkin+Lymphoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-21T23:50:00.508Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03739619", "title": "Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma", "Classical Hodgkin Lymphoma", "Hodgkin Lymphoma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2018-11-26", "completion_date": "2025-04-30", "has_results": true, "last_update_posted_date": "2025-08-06", "last_synced_at": "2026-05-21T23:50:00.508Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03739619" }, { "nct_id": "NCT00587912", "title": "AIDS and Cancer Specimen Bank (ACSB)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Kaposi's Sarcoma AIDS Related", "Kaposi's Sarcoma Classical", "Non-Hodgkin's Lymphoma", "HEMATOPOIETIC SYSTEM", "Cancer", "AIDS" ], "interventions": [], "intervention_types": [], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "1997-06", "completion_date": "2011-04", "has_results": false, "last_update_posted_date": "2011-04-21", "last_synced_at": "2026-05-21T23:50:00.508Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00587912" }, { "nct_id": "NCT02168140", "title": "CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Lymphocyte Depletion Hodgkin Lymphoma", "Adult Lymphocyte Predominant Hodgkin Lymphoma", "Adult Mixed Cellularity Hodgkin Lymphoma", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Adult Nodular Sclerosis Hodgkin Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Hepatosplenic T-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "T-cell Adult Acute Lymphoblastic Leukemia", "T-cell Large Granular Lymphocyte Leukemia" ], "interventions": [ { "name": "6,8-bis(benzylthio)octanoic acid", "type": "DRUG" }, { "name": "bendamustine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2014-09", "completion_date": "2022-09-15", "has_results": false, "last_update_posted_date": "2024-02-13", "last_synced_at": "2026-05-21T23:50:00.508Z", "location_count": 2, "location_summary": "Winston-Salem, North Carolina • Philadelphia, Pennsylvania", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02168140" }, { "nct_id": "NCT06745076", "title": "Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Hodgkin Lymphoma", "Classic Hodgkin Lymphoma", "Lugano Classification Stage III Hodgkin Lymphoma AJCC v8", "Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Questionnaire", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2025-03-06", "completion_date": "2033-01-03", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-05-21T23:50:00.508Z", "location_count": 5, "location_summary": "Irvine, California • Boston, Massachusetts • St Louis, Missouri + 2 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06745076" }, { "nct_id": "NCT05140382", "title": "AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed/Refractory Peripheral T-cell Lymphoma", "Relapsed/Refractory Classical Hodgkins Lymphoma" ], "interventions": [ { "name": "AZD4573", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 52, "start_date": "2021-12-15", "completion_date": "2024-02-16", "has_results": true, "last_update_posted_date": "2024-08-28", "last_synced_at": "2026-05-21T23:50:00.508Z", "location_count": 6, "location_summary": "Duarte, California • Boston, Massachusetts • Hackensack, New Jersey + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05140382" }, { "nct_id": "NCT00439361", "title": "Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkin Lymphoma", "Lymphoma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 14, "start_date": "2007-02", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2012-07-09", "last_synced_at": "2026-05-21T23:50:00.508Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00439361" }, { "nct_id": "NCT00004031", "title": "SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "CHOP regimen", "type": "DRUG" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "15 Years to 65 Years" }, "enrollment_count": 397, "start_date": "1997-07", "completion_date": "2013-10-31", "has_results": true, "last_update_posted_date": "2021-02-02", "last_synced_at": "2026-05-21T23:50:00.508Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004031" }, { "nct_id": "NCT04268706", "title": "Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma, Adult", "Hodgkin Disease Recurrent", "Hodgkin Disease Refractory", "Hodgkin Disease, Pediatric" ], "interventions": [ { "name": "CD30.CAR-T", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tessa Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 97, "start_date": "2021-02-01", "completion_date": "2037-03", "has_results": false, "last_update_posted_date": "2023-04-05", "last_synced_at": "2026-05-21T23:50:00.508Z", "location_count": 5, "location_summary": "Duarte, California • Chicago, Illinois • Philadelphia, Pennsylvania + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04268706" }, { "nct_id": "NCT05255601", "title": "A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Hodgkin Disease" ], "interventions": [ { "name": "Relatlimab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 5, "start_date": "2022-09-13", "completion_date": "2025-12-03", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-05-21T23:50:00.508Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05255601" }, { "nct_id": "NCT00301860", "title": "Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 8, "start_date": "2003-01", "completion_date": "2007-11", "has_results": false, "last_update_posted_date": "2013-07-15", "last_synced_at": "2026-05-21T23:50:00.508Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00301860" } ] }